title: New therapeutic approaches to reversing insulin resistance.
abstract: Insulin resistance may be associated with hypertension and additional cardiovascular disease risk factors. Troglitazone, a thiazolidinedione, is an insulin sensitizing agent that has recently been approved by the USA Food and Drug Administration for the treatment of type II diabetes. Thiazolidinediones and other agents that increase insulin sensitivity, and lipid lowering drugs attenuate the development of hypertension in animal models and in limited clinical studies.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.
authors.forename: G E
authors.initials: GE
authors.lastname: Sonnenberg
authors.forename: T A
authors.initials: TA
authors.lastname: Kotchen
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002839:Chromans / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077288:Troglitazone